Harold E. Selick - 27 May 2021 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Reporting relationship: Director
Issuer ticker: PTGX
Reported as of: 27 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2021, 19:00:57 UTC
Next SEC filing: 04 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Donald Kalkofen, Attorney-in-Fact for Harold E. Selick

Key filing fact

Harold E. Selick filed Form 4 for Protagonist Therapeutics, Inc (PTGX) on 28 May 2021.

Key facts

This page summarizes Harold E. Selick's Form 4 filing for Protagonist Therapeutics, Inc (PTGX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 May 2021, 19:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTGX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +18,000
Change %
Price: $0.000000
Shares after: 18,000
Date: 27 May 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,000
Exercise price: $35.23
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest at the earlier of (i) May 27, 2022, or (ii) the date of the 2022 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan).